Adial Pharmaceuticals (ADIL) Short term Debt (2018)
Adial Pharmaceuticals (ADIL) posted Short term Debt of $138603.0 for Q3 2018, up 383.34% sequentially from $28676.0 in Q2 2018.
Adial Pharmaceuticals (ADIL) Short term Debt (2018) Analysis & Trends
Adial Pharmaceuticals has reported Short term Debt for 1 years, with the latest figure at $138603.0 in Q3 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.54 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.27 Bn | 60.09 Bn | 1.37 Bn |
| 4 | Moderna | 59.41 Bn | 54.27 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.07 Bn | 9.68 Bn | 668.28 Mn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.44 Bn | - |
| 10 | Adial Pharmaceuticals | 27.59 Mn | 27.59 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 138,603.00 |
| Jun 30, 2018 | 28,676.00 |